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Abstract
Background: High blood pressure is an important determinant of cardiovascular disease risk. Treated hypertensives do
not attain a risk level equivalent to normotensives. This may be a consequence of suboptimal blood pressure control to
which indiscriminate use of antihypertensive drugs may contribute. Indeed the recent ALLHAT[1]study suggests that
thiazides should be given first to virtually all hypertensives. Whether this is correct or whether different antihypertensive
therapies should be targeted towards different patients is a major unresolved issue, which we address in this study.
The measurement of the ratio of aldosterone: renin is used to identify hypertensive subjects who may respond well to
treatment with the aldosterone antagonist spironolactone. It is not known if subjects with a high ratio have aldosteronism
or aldosterone-sensitive hypertension is debated but it is important to know whether spironolactone is superior to other
diuretics such as bendroflumethiazide in this setting.
Methods/design: The study is a double-blind, randomised, crossover, controlled trial that will randomise 120
hypertensive subjects to 12 weeks treatment with spironolactone 50 mg once daily and 12 weeks treatment with
bendroflumethiazide 2.5 mg once daily. The 2 treatment periods are separated by a 2-week washout period.
Randomisation is stratified by aldosterone: renin ratio to include equal numbers of subjects with high and low
aldosterone: renin ratios.
Primary Objective – To test the hypothesis that the aldosterone: renin ratio predicts the antihypertensive response to
spironolactone, specifically that the effect of spironolactone 50 mg is greater than that of bendroflumethiazide 2.5 mg in
hypertensive subjects with high aldosterone: renin ratios.
Secondary Objectives – To determine whether bendroflumethiazide induces adverse metabolic abnormalities, especially
in subjects with high aldosterone: renin ratios and if baseline renin measurement predicts the antihypertensive response
to spironolactone and/or bendrofluazide
Discussion: The numerous deleterious effects of hypertension dictate the need for a systematic approach for its
treatment. In spite of various therapies, resistant hypertension is widely prevalent. Among various factors, primary
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BMC Cardiovascular Disorders 2007, 7:14 http://www.biomedcentral.com/1471-2261/7/14aldosteronism is an important cause of resistant hypertension and is now more commonly recognised. More significantly,
hypertensives with primary aldosteronism are also exposed to various other deleterious effects of excess aldosterone.
Hence treating hypertension with specific aldosterone antagonists may be a better approach in this group of patients. It
may lead on to better blood pressures with fewer medications.
Background
Epidemiology
One approach to more effective antihypertensive control
would be to target aldosterone antagonists towards
patients in whom these drugs are likely to work best.
Hyperaldosteronism is characterised by excessive excre-
tion of aldosterone with concomitant suppression of
renin associated with hypertension. However, neither
aldosterone excretion nor plasma renin activity alone has
proved useful in screening for this condition for a variety
of reasons. Hiramatsu and colleagues have suggested that
the aldosterone: renin ratio may be a useful screening
test[2]. Using the aldosterone: renin ratio to find possible
cases, Gordon and colleagues reported that hyperaldos-
teronism was more common than suspected, with 8% of
cases referred to his clinic having this condition[3]. A high
aldosterone: renin ratio has been found in 15% of a UK
hypertension clinic[4] and the general community[5].
There is debate as to whether a raised ratio defines aldos-
teronism or whether it detects a subgroup of subjects with
aldosterone-sensitive hypertension, although subjects
with a raised ratio do appear to have genetic differences
from those who do not[6]. If further testing is undertaken,
94% of clinic subjects with a raised ratio did not suppress
plasma aldosterone with salt loading, a test many regard
as diagnostic[4]. However, salt-loading is not without
risks[7] and a simple blood test that was able to guide
appropriate therapy is an attractive concept.
Rationale for study
Most subjects with a raised aldosterone: renin ratio do not
have distinct metabolic abnormalities. Furthermore, if
they are investigated, most do not have adrenal adeno-
mas; instead they have adrenal hyperplasia or even nor-
mal sized adrenal glands. While some authorities
recommend full investigation and laparoscopic adrenal-
ectomy if excessive aldosterone secretion can be lateral-
ised to one of the glands[8,9], surgery is not without risks
and 60% of adrenalectomised subjects require antihyper-
tensive therapy[10]. In addition, those who have a good
response to surgery also show a good response to
spironolactone[11] and long term drug treatment is safe
and effective[12]. Furthermore, there remains some
debate about the true distinction between genuine auton-
omous primary aldosteronism and relative aldosterone
excess association with low renin hypertension. The pur-
pose of the proposed study is not to resolve this argument,
but instead to answer a pragmatic question about the best
treatment of patients with resistant hypertension. There is
no argument that patients with a high aldosterone: renin
ratio may have resistant hypertension. It is also clear that
the number of patients with a high ratio forms a large sub-
group of patients with high blood pressure. Aldosterone
has deleterious effects on the cardiovascular system and it
is possible that patients with hypertension who have a
high aldosterone: renin ratio are at particular risk of cardi-
ovascular morbid events. Thus, it is of considerable prac-
tical importance to define what treatment provides best
blood pressure lowering and cardiovascular protection to
these subjects [13-15] In this regard, a recent observa-
tional study done by one of the authors provides some
evidence that subjects with a raised aldosterone: renin
ratio had good anti-hypertensive responses to more usual
doses of spironolactone (25–100 mg)[16]. Importantly,
the subjects treated with spironolactone had better blood
pressure control with fewer antihypertensive drug treat-
ments after spironolactone was commenced.
There is on going debate on the topic of the aldosterone:
renin ratio and its role, if any, in subjects with hyperten-
sion. It is true that we need better evidence of the practical
value of measuring the ratio before we recommend
change to current practice and treat patients with
spironolactone. A key question is "would such a strategy
be better than treating all subjects conventionally with a
thiazide diuretic?"
Rationale for doses of bendroflumethiazide and 
spironolactone
Previous studies with thiazide diuretics have suggested
that the dose-response relationship is shallow. With ben-
droflumethiazide, the most commonly used thiazide in
the UK, 2.5 mg is almost as effective as 5 mg and as a con-
sequence very few physicians use the higher dose. In
essential hypertension, a similar dose-response relation-
ship is true for spironolactone but higher doses of
spironolactone may reduce BP more in those with high
aldosterone: renin ratios. In one sense, the ideal compari-
son would be between exactly equipotent doses of these
two drugs. However, the critical question is whether the
efficacy of the usually prescribed doses of these drugs is
predicted by the aldosterone: renin ratio. This is the prag-
matic question that is relevant to day-to-day clinical prac-
tice. In order to test this hypothesis, it is not necessary for
the doses employed to be exactly equipotent. For this rea-
son we have chosen 50 mg of spironolactone, to be com-Page 2 of 8
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commonly used doses of each drug.
Rationale for choice of subjects
In an ideal study, subjects would be untreated at entry.
However, patients with high aldosterone: renin ratios
tend to have resistant hypertension. For ethical reasons, it
is not possible to discontinue anti-hypertensive therapy in
such individuals. In addition, in a pragmatic study allow-
ing drug treatment at entry will result in the study popula-
tion being more representative of the true patient
population. We recognise that it is necessary to restrict the
types of drug therapy used for the duration of the trial to
maximise the information gained from the randomised
arms. Although some drugs may independently affect
renin and aldosterone, in a crossover trial these effects
should be balanced. Thus, subjects taking medication at
screening continue on or are changed to standard open
drug therapy to control blood pressure in the following
order of preference: alpha-blockers, centrally acting drugs,
calcium channel blockers, cardio-selective beta blockers
and (exceptionally) ACE inhibitors and angiotensin
receptor blockers. Allowing subjects into the study who
are hypertensive on drug therapy enriches the study pop-
ulation with cases of resistant hypertension. We accept
that this may bias the study towards a secondary care type
of population, but we believe that many such patients do
exist in primary care, albeit in smaller numbers and that
the study will still be relevant to that setting.
Methods/design
Study design
The study is a double-blind, randomised, crossover, con-
trolled trial that will randomise 120 hypertensive subjects
to 12 weeks treatment with spironolactone 50 mg once
daily and 12 weeks treatment with bendroflumethiazide
2.5 mg once daily. The 2 treatment periods are separated
by a 2-week washout period. Investigators and subjects do
not know the order of the treatment periods, which is
according to a computer generated randomisation list.
Randomisation is stratified by aldosterone: renin ratio to
include equal numbers of subjects with high and low
aldosterone: renin ratios. This is necessary as in an unse-
lected population, only 15% of subjects will have an
aldosterone: renin ratio > 750.
Study population
Potential study subjects with mild-moderate hypertension
are identified from clinic patients or from community
treated patients.
Inclusion/exclusion criteria
Screening
Written informed consent is obtained prior to carrying out
screening procedures. Potential subjects are assigned a
subject number. Antihypertensive therapy may not be
necessarily be discontinued[17] but may be in some cases,
or it may be adjusted if necessary. Specifically, potential
subjects on spironolactone, and for whom, in the opinion
of the investigator, there is no compelling indication not
to discontinue this for the purpose of taking part in the
study, may have this drug discontinued 3 months prior to
entry, provided full written informed consent is obtained.
Diuretics should be discontinued for a minimum of 2
weeks prior to entry and also beta-blockers, where possi-
ble. Alternative antihypertensive treatment may be substi-
tuted.
Medical history, concomitant conditions and medications
are recorded and a physical examination carried out.
Height and weight are measured. Blood pressure is meas-
ured using the OMRON 705CP[18]. The mean of three
readings is taken after two minutes rest in the sitting posi-
tion with the arm supported at the level of the heart. A 12-
lead ECG and clinical laboratory tests including urinaly-
sis, blood biochemistry and haematology are carried out.
Blood samples for measurement of plasma aldosterone
and plasma renin activity are taken (after 5 min sitting
quietly).
Subjects undergo ambulatory blood pressure monitoring
for 26 hours using Spacelabs 90207 monitor. This is set to
take readings every 15 minutes during daytime (0800 h–
2159 h) and every 30 minutes during night time (2200 h–
0759 h). To be considered evaluable, the ABPM report
must contain at least 24 hours data, including at least one
valid reading for every hour during daytime and every 2
hours during night time. To fulfil the inclusion criteria,
mean daytime systolic BP on screening ABPM must be at
least 140 mmHg.
Randomisation
Blood samples for aldosterone and renin, from subjects
who fulfil all other inclusion criteria, are analysed by a
central laboratory.
Stratified randomisation
The aldosterone: renin ratio calculated by the central lab-
oratory is used to stratify subjects. For the purposes of this
study subjects must have either a high aldosterone: renin
ratio > 750 with a plasma aldosterone > 250 pmol/l or a
low aldosterone: ratio < 300 with plasma renin activity
<10 ng/ml/h.
Follow-up visits
Randomised subjects are seen at one week, four weeks,
eight weeks and twelve weeks during each treatment
phase. On each occasion blood pressure is measured
using OMRON 705CP and a safety blood sample taken
for potassium, magnesium and creatinine. Subjects arePage 3 of 8
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changes in concomitant medication. Investigators may
repeat ambulatory blood pressure monitoring at follow-
up visits if they wish to. These data will not be used in the
analysis.
On the penultimate day of each treatment period subjects
have Omron BP measurements prior to fitting an ambula-
tory blood pressure monitor. On their return 26 hours
later, on their final day of treatment, subjects again have
Omron BP measurements. The mean of these two mean
Renaldo Study DesignFigure 1
Renaldo Study Design.Page 4 of 8
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Mean daytime ambulatory blood pressure and mean
night time blood pressure are also secondary blood pres-
sure endpoints. The primary endpoint is mean 24-hour
blood pressure.
At the end of the study, subjects are commenced or con-
tinued on standard anti-hypertensive therapy and fol-
lowed up as per usual clinical care.
Safety considerations
Assessments
Safety assessments consist of monitoring and recording all
adverse events (AEs) and serious adverse events (SAEs),
measurement of blood pressure and heart rate, monitor-
ing of blood biochemistry, ECG recordings and physical
examination if indicated.
Uncontrolled blood pressure
If blood pressure is uncontrolled investigators may use
their discretion and add further antihypertensive medica-
tion in the following order of preference: alpha-blockers,
centrally acting drugs, calcium channel blockers, cardio-
selective beta blockers and (exceptionally) ACE inhibitors
and angiotensin receptor blockers. A log of all medication
taken during the study is kept for each subject.
Symptomatic hypotension
If the investigator suspects that a subject is suffering symp-
tomatic hypotension, then open-label anti-hypertensive
medication can be withdrawn or study medication can be
reduced to one capsule every second day.
Hypokalaemia/hyperkalaemia
Subjects who develop hypokalaemia (K+ < 3.5 mmol/l)
are given slow release potassium supplementation 600
mg three times daily. If hypokalaemia is deemed severe
(K+ < 3 mmol/l) study medication is discontinued for
three days or until K+ is > 3.5 mmol/l whereupon study
medication is restarted at one capsule taken every second
day along with potassium supplementation. Subjects who
subsequently develop hypokalaemia have study medica-
tion withdrawn. Similarly, study medication is stopped
temporarily and restarted at half dosage if plasma K+ > 5.5
mmol/l.
Endpoints
Primary endpoint
The primary endpoint is the difference in mean 24-hour
systolic ambulatory blood pressure recorded at the end of
each 12-week treatment period.
Secondary endpoints
Secondary endpoints include the differences between the
following measurements taken at the end of each 12-week
treatment period
• Mean 24 hour diastolic ambulatory blood pressure
• Mean daytime ambulatory blood pressure
• Mean night time ambulatory blood pressure
• Mean clinic blood pressure defined as mean of mean
clinic BPs on both penultimate and final days of treatment
periods
• Clinical biochemistry measurements of plasma potas-
sium (K+), magnesium (Mg2+), creatinine, triglycerides,
cholesterol and HDL cholesterol
Statistical analysis
Power calculations and sample size
Power calculations are based on a standard deviation of
11 mmHg for ambulatory systolic BP and 7 mmHg for
ambulatory diastolic BP. A sample size of 28 in each stra-
tum of aldosterone: renin ratio would give 80% power to
detect a 6 mmHg difference in ambulatory systolic BP and
4 mmHg difference in diastolic BP between spironolac-
tone and bendroflumethiazide treatments. However, we
are interested in detecting differences in BP changes com-
paring the low-ratio and high-ratio arms. We therefore
Inclusion/Exclusion criteriaFig re 2
Inclusion/Exclusion criteria.Page 5 of 8
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4 mmHg difference in BP at the α = p < 0.05 (two-sided).
Therefore, allowing for dropouts, a sample size of 60 in
each arm or 120 subjects in total are required. A multivar-
iate analysis to investigate the effect of age and other char-
acteristics on the effects of Spironolactone is also planned.
Analyses
For each outcome the measurement from the spironolac-
tone treatment period will be subtracted from that of the
bendroflumethiazide treatment period. Therefore each
person has an estimated "treatment effect". The mean dif-
ference, between the treatment effects in the high ratio
group and those in the low ratio group, will be compared
by t-tests and 95% confidence intervals. There may be
some secondary Normal Linear Models that also examine
other factors, which may also be considered to be con-
founders, as this is a non-randomised comparison.
The second analysis will be by conventional crossover
analyses of the efficacy of spironolactone (in the high-
ratio sub-group only). These analyses will be carried out
by Normal Linear Models, that include parameters for
patient, period and treatment. In the event that a variable
is not normally distributed then the within-patient treat-
ment differences will be calculated and then analysed by
either t-tests or Wilcoxon tests.
Substudies
The reason for these sub-studies is that the indices meas-
ured (QT dispersion, heart rate variability, endothelial
function and exercise BP) are considered reasonably good
surrogates for future cardiovascular events and mortality
[19-21] Certainly, in the case of chronic heart failure, the
spironolactone-induced improvement in mortality in
Randomised Aldactone Evaluation Study (RALES) [22]
was paralleled by spironolactone induced improvements
in QT dispersion, heart rate variability[23] and endothe-
lial function[24]. The results of these substudies may be
useful indicators of future cardiovascular outcomes.
QT dispersion
QT dispersion is measured from routine ECGs recorded at
baseline and at the end of each treatment period.
Spironolactone has been shown to reduce QT dispersion
in chronic heart failure[23] and it is of interest to investi-
gate whether this is also the case in hypertension and
whether such an effect is more prominent in subjects with
a high aldosterone: renin ratio.
Heart rate variability
Heart rate variability is assessed from 24-hour ambulatory
ECG monitoring carried out at the end of each treatment
phase. Again, spironolactone has been shown to improve
the parasympathetic component of heart rate variabil-
ity[23] and it is of interest to examine if this is also the case
in hypertension and whether such an effect is more prom-
inent in subjects with a high aldosterone: renin ratio. Ven-
tricular ectopic activity on the 24 hr tapes is also
measured.
Endothelial function
A subset of the subjects undergoes endothelial function
assessment by a standard protocol. At the end of each
treatment period, these subjects undergo a detailed bra-
chial artery infusion study with sequential infusions of
acetylcholine, nitroprusside and LNMMA (NG-monome-
thyl-L-arginine) combined. In CHF, spironolactone
improves endothelial function[24] even in the presence of
an ACE inhibitor. It will therefore be of major interest to
see the effect of spironolactone in hypertension and
whether such an effect is more prominent in subjects with
a high aldosterone: renin ratio.
Pulsewave analysis and velocity
In parallel with the detailed invasive assessment of
endothelial function described above, a larger cohort of
each sub-group undergoes a non-invasive measurement
of vascular compliance and pulse waveform characteris-
tics using the Sphygmocor technique. This measurement
is likely to be influenced by the baseline ratio, and for this
reason balanced numbers of subjects in each subset are
recruited. This measurement will be made at the end of
each treatment period.
Exercise blood pressure
All subjects also have their blood pressure measured after
a 3-minute exercise step-test, The Dundee Step Test. Pre-
liminary data suggests that exercise BP is correlated with
the aldosterone: renin ratio[25].
Plasma and urinary steroids
A blood sample for plasma steroids is taken at baseline. A
24 h urine collection is also done and will be analysed for
electrolytes, aldosterone and urinary steroids including
18-oxocortisol. These data will be used to investigate if
there are any predictors of the BP response that are supe-
rior to the aldosterone: renin ratio.
Plasma PIIINP (Procollagen Type III N-terminal Peptide)
Plasma PIIINP is a marker for collagen formation in the
heart and spironolactone has been found to reduce PII-
INP in heart failure[26]. We wish to examine whether if
this is also the case in hypertension.
DNA
A blood sample is drawn to assess the effect of polymor-
phic variation at the aldosterone synthase (CYP11B2)
gene (SF1, 344T/C and intron 2 conversion) on baseline
phenotypic abnormalities and response to therapy. InPage 6 of 8
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corticoid remediable aldosteronism (GRA).
Ethical approval
The main study and sub-studies have ethical approval
from Tayside Committee on Medical Research Ethics and
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Discussion
The numerous deleterious effects of hypertension[27] dic-
tate the need for a systematic approach for its treatment.
In spite of various therapies, resistant hypertension is
widely prevalent [28]. Among various factors, primary
aldosteronism is an important cause of resistant hyperten-
sion and is now more commonly recognised[4,5,29].
Moreover even in treated hypertensives, the mortality
remains up to five times higher compared to normoten-
sives[30]. One of the factors might be inadequate blood
pressure control due to usage of inappropriate drugs.
More significantly, hypertensives with primary aldos-
teronism are also exposed to various other deleterious
effects of excess aldosterone [31]. Aldosterone has delete-
rious effects on the myocardium and induces myocardial
hypertrophy, fibrosis and necrosis[32,33]. Aldosterone is
implicated in heart failure and its blockade in significantly
reduces mortality[22,34]. Aldosterone also induces
endothelial dysfunction[35]. Hence treating hypertension
with specific aldosterone antagonists may be a better
approach in this group of patients. It may lead on to better
blood pressures with fewer medications[16].
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